Effects and side-effects of spironolactone therapy in women with acne

Basit Öğe Kaydı
dc.authoridPISKIN, SULEYMAN/0000-0002-0999-2267
dc.authorwosidPişkin, Süleyman/ABC-2562-2020
dc.contributor.authorYemisci, A
dc.contributor.authorGorgulu, A
dc.contributor.authorPiskin, S
dc.date.accessioned2024-06-12T10:50:28Z
dc.date.available2024-06-12T10:50:28Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and aims Androgen hormones play an important role in the pathogenesis of acne. Despite the demonstrated effects, spironolactone, an androgen receptor blocker, is not commonly used to treat acne. We planned an open-labelled, prospective study to evaluate the effects and side-effects of spironolactone therapy in women with acne. Materials and methods Thirty-five consecutive patients with acne were treated with spironolactone 100 mg/day, 16 days each month for 3 months. The patients were divided according to the clinical severity of the lesions as having mild, moderate and severe acne. Serum total testosterone and dehydroepiandrosterone sulfate (DHEAS) levels were measured before and after treatment. Lesion numbers and hormone levels before and after treatment were compared with one-sampled t-test. Results The mean age of the patients was 21.4 +/- 3.5 years.Two patients discontinued the study due to sideeffects. Five patients were lost in the follow-up. Clinically significant improvement was noted in 24 patients (85.71%). No response was seen in four patients. All of the nonresponding patients had received previous unsuccessful therapies. Mean number of lesions and mean DHEAS levels of the 24 patients with clinical improvement decreased significantly after treatment (P < 0.01 and P < 0.05, respectively). There was no change in the mean total testosterone levels before and after treatment (P > 0.05). Conclusion Spironolactone is a safe and effective medication for women with acne vulgaris. Although its side-effects seem to be high, they are in the majority of cases not a reason to stop treatment.en_US
dc.identifier.doi10.1111/j.1468-3083.2005.01072.x
dc.identifier.endpage166en_US
dc.identifier.issn0926-9959
dc.identifier.issn1468-3083
dc.identifier.issue2en_US
dc.identifier.pmid15752283en_US
dc.identifier.scopus2-s2.0-16244373761en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage163en_US
dc.identifier.urihttps://doi.org/10.1111/j.1468-3083.2005.01072.x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17999
dc.identifier.volume19en_US
dc.identifier.wosWOS:000228275500004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of The European Academy Of Dermatology And Venereologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcne Vulgarisen_US
dc.subjectEffectivenessen_US
dc.subjectSpironolactoneen_US
dc.subjectTolerabilityen_US
dc.subjectOral Spironolactoneen_US
dc.subjectHirsutismen_US
dc.subjectVulgarisen_US
dc.titleEffects and side-effects of spironolactone therapy in women with acneen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu